AbbVie
ABBV
$166.42
Share price
1.26%
Change (1 day)
16.09%
Change (1 year)
Categories
The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol “ABBV”.
AbbVie (ABBV) - P/B ratio
P/B ratio as of May 2024 : 27.9
According to AbbVie's latest financial reports the company has a price-to-book ratio of 27.9.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
AbbVie - P/B ratio (from 2012 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | 26.3 | 59.17% |
| 2022-12-31 | 16.5 | 6.61% |
| 2021-12-31 | 15.5 | 7.36% |
| 2020-12-31 | 14.4 | -190.14% |
| 2019-12-31 | -16.0 | -0.73% |
| 2018-12-31 | -16.1 | -153.29% |
| 2017-12-31 | 30.3 | 37.99% |
| 2016-12-31 | 22.0 | -9.2% |
| 2015-12-31 | 24.2 | -59.56% |
| 2014-12-31 | 59.8 | 220.35% |
| 2013-12-31 | 18.7 | 16.28% |
| 2012-12-31 | 16.0 | |
| 2011-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 1.84 | -93.42% | 🇺🇸 USA |
 Eli Lilly LLY | 56.8 | 103.57% | 🇺🇸 USA |
 Amgen AMGN | 27.1 | -2.95% | 🇺🇸 USA |
 Biogen BIIB | 2.20 | -92.11% | 🇺🇸 USA |
 Gilead Sciences GILD | 3.72 | -86.69% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 5.40 | -80.64% | 🇺🇸 USA |
 AstraZeneca AZN | 6.37 | -77.18% | 🇬🇧 UK |
 GlaxoSmithKline GSK | 5.54 | -80.17% | 🇬🇧 UK |
 Neurocrine Biosciences
NBIX | 5.99 | -78.56% | 🇺🇸 USA |